-
Mashup Score: 35Results from Study of Pembrolizumab in Muscle-invasive and Locally Advanced Urothelial Carcinoma - 2 month(s) ago
Get the results from the AMBASSADOR study presented by Dr. Andrea Apolo from the National Cancer Institute at ASCO GU 2024 in this MEDtalk. The study is a multi-center phase III trial investigating the efficacy of adjuvant pembrolizumab versus observation in patients with muscle-invasive urothelial carcinoma. Notably, disease-free survival extended to a median of 29 months compared to 14 months in the control group. Despite the overall survival data still maturing, this study paves the way for pembrolizumab as a potential treatment option for patients post-radical surgery and elaborates on the prognostic role of PD-L1 status and how it shapes treatment decisions within this patient demographic.
Source: bpno.dkCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 31Results from Study of Pembrolizumab in Muscle-invasive and Locally Advanced Urothelial Carcinoma - 3 month(s) ago
Get the results from the AMBASSADOR study presented by Dr. Andrea Apolo from the National Cancer Institute at ASCO GU 2024 in this MEDtalk. The study is a multi-center phase III trial investigating the efficacy of adjuvant pembrolizumab versus observation in patients with muscle-invasive urothelial carcinoma. Notably, disease-free survival extended to a median of 29 months compared to 14 months in the control group. Despite the overall survival data still maturing, this study paves the way for pembrolizumab as a potential treatment option for patients post-radical surgery and elaborates on the prognostic role of PD-L1 status and how it shapes treatment decisions within this patient demographic.
Source: bpno.dkCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 30Results from Study of Pembrolizumab in Muscle-invasive and Locally Advanced Urothelial Carcinoma - 3 month(s) ago
Get the results from the AMBASSADOR study presented by Dr. Andrea Apolo from the National Cancer Institute at ASCO GU 2024 in this MEDtalk. The study is a multi-center phase III trial investigating the efficacy of adjuvant pembrolizumab versus observation in patients with muscle-invasive urothelial carcinoma. Notably, disease-free survival extended to a median of 29 months compared to 14 months in the control group. Despite the overall survival data still maturing, this study paves the way for pembrolizumab as a potential treatment option for patients post-radical surgery and elaborates on the prognostic role of PD-L1 status and how it shapes treatment decisions within this patient demographic.
Source: bpno.dkCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 28Results from Study of Pembrolizumab in Muscle-invasive and Locally Advanced Urothelial Carcinoma - 3 month(s) ago
Get the results from the AMBASSADOR study presented by Dr. Andrea Apolo from the National Cancer Institute at ASCO GU 2024 in this MEDtalk. The study is a multi-center phase III trial investigating the efficacy of adjuvant pembrolizumab versus observation in patients with muscle-invasive urothelial carcinoma. Notably, disease-free survival extended to a median of 29 months compared to 14 months in the control group. Despite the overall survival data still maturing, this study paves the way for pembrolizumab as a potential treatment option for patients post-radical surgery and elaborates on the prognostic role of PD-L1 status and how it shapes treatment decisions within this patient demographic.
Source: bpno.dkCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 12
In this MEDtalk, Dr. Amer Zeidan, Associate Professor of Medicine at Yale University, shares data on the effectiveness of oral decitabine (DEC-C) for Myelodysplastic Syndrome (MDS) in a real-life analysis.
Source: bpno.dkCategories: General Medicine News, Hem/OncsTweet
RT @apolo_andrea: Brief summary of the AMBASSADOR study https://t.co/usecTf79Wz @OncoAlert @OncBrothers @bergsa83 @morr316 @PGrivasMDPhD @B…